論文

国際誌
2021年

Intestinal Dysbiosis and Autoimmune Pancreatitis.

Frontiers in immunology
  • Tomoe Yoshikawa
  • ,
  • Tomohiro Watanabe
  • ,
  • Ken Kamata
  • ,
  • Akane Hara
  • ,
  • Kosuke Minaga
  • ,
  • Masatoshi Kudo

12
開始ページ
621532
終了ページ
621532
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3389/fimmu.2021.621532

Autoimmune pancreatitis (AIP) is a chronic fibro-inflammatory disorder of the pancreas. Recent clinicopathological analysis revealed that most cases of AIP are pancreatic manifestations of systemic IgG4-related disease (IgG4-RD), a newly established disease characterized by enhanced IgG4 antibody responses and the involvement of multiple organs. Although the immuno-pathogenesis of AIP and IgG4-RD has been poorly defined, we recently showed that activation of plasmacytoid dendritic cells (pDCs) with the ability to produce large amounts of IFN-α and IL-33 mediates chronic fibro-inflammatory responses in experimental and human AIP. Moreover, M2 macrophages producing a large amount of IL-33 play pathogenic roles in the development of human IgG4-RD. Interestingly, recent studies including ours provide evidence that compositional alterations of gut microbiota are associated with the development of human AIP and IgG4-RD. In addition, intestinal dysbiosis plays pathological roles in the development of chronic pancreatic inflammation as dysbiosis mediates the activation of pDCs producing IFN-α and IL-33, thereby causing experimental AIP. In this Mini Review, we focus on compositional alterations of gut microbiota in AIP and IgG4-RD to clarify the mechanisms by which intestinal dysbiosis contributes to the development of these disorders.

リンク情報
DOI
https://doi.org/10.3389/fimmu.2021.621532
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33833754
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021793
ID情報
  • DOI : 10.3389/fimmu.2021.621532
  • PubMed ID : 33833754
  • PubMed Central 記事ID : PMC8021793

エクスポート
BibTeX RIS